Cargando…

A PPARα agonist improves metabolic parameters in obesity

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Company of Biologists Limited 2012
Materias:	In this Issue
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424444/

Ejemplares similares

PPARα-Independent Arterial Smooth Muscle Relaxant Effects of PPARα Agonists
por: Silswal, Neerupma, et al.
Publicado: (2012)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Role of PPARα and Its Agonist in Renal Diseases
por: Cheng, Ching-Feng, et al.
Publicado: (2010)

PPARα Agonist Oral Therapy in Diabetic Retinopathy
por: Tomita, Yohei, et al.
Publicado: (2020)

The Effects of New Selective PPARα Agonist CP775146 on Systematic Lipid Metabolism in Obese Mice and Its Potential Mechanism
por: Tang, Shengjie, et al.
Publicado: (2020)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

AMPK-Dependent Metabolic Regulation by PPAR Agonists
por: Lee, Woo Hyung, et al.
Publicado: (2010)

PPAR Agonists and Metabolic Syndrome: An Established Role?
por: Botta, Margherita, et al.
Publicado: (2018)

PPARγ tackles treacherous T cells
por: Leslie, Mitch
Publicado: (2009)

The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice
por: Araki, Masaya, et al.
Publicado: (2018)

The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism()()
por: Huang, Jianfeng, et al.
Publicado: (2013)

Dual PPAR α/γ Agonists: Continuing Cardiac Concerns
por: Balachandran, Karthik
Publicado: (2019)

Effects of Endogenous PPAR Agonist Nitro-Oleic Acid on Metabolic Syndrome in Obese Zucker Rats
por: Wang, Haiping, et al.
Publicado: (2010)

The Effect of PPARα, PPARδ, PPARγ, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice
por: Harrington, W. Wallace, et al.
Publicado: (2007)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

Crosstalk between CYP2E1 and PPARα substrates and agonists modulate adipose browning and obesity
por: Zhang, Youbo, et al.
Publicado: (2022)

Effects of the PPARα Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism
por: Cunningham, Michael L., et al.
Publicado: (2010)

Therapeutic potential of PPARα agonist in ligature-induced experimental periodontitis
por: Chen, Ying, et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
por: Jani, Rajendra H., et al.
Publicado: (2013)

Obesity and the microbiome in atopic dermatitis: Therapeutic implications for PPAR-γ agonists
por: McAleer, Jeremy P.
Publicado: (2023)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
por: Jain, Mukul R., et al.
Publicado: (2017)

Structural Basis for PPARs Activation by The Dual PPARα/γ Agonist Sanguinarine: A Unique Mode of Ligand Recognition
por: Tian, Siyu, et al.
Publicado: (2021)

The PPARα/γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat
por: Wallenius, Kristina, et al.
Publicado: (2013)

Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARα + γ Agonists
por: Oleksiewicz, Martin B., et al.
Publicado: (2008)

Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
por: Cariou, Bertrand, et al.
Publicado: (2011)

Treatment of Obesity-Related Complications with Novel Classes of Naturally Occurring PPAR Agonists
por: Bassaganya-Riera, Josep, et al.
Publicado: (2011)

Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK
por: Sandoval‐Rodriguez, Ana, et al.
Publicado: (2020)

Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models
por: Jain, Mukul R, et al.
Publicado: (2015)

Cardiac dysfunction in adipose triglyceride lipase deficiency: treatment with a PPARα agonist
por: Wölkart, G, et al.
Publicado: (2012)

Effects of PPARs Agonists on Cardiac Metabolism in Littermate and Cardiomyocyte-Specific PPAR-γ –Knockout (CM-PGKO) Mice
por: Barbieri, Michelangela, et al.
Publicado: (2012)

A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia
por: Balakumar, Pitchai, et al.
Publicado: (2019)

PPARα in Obesity: Sex Difference and Estrogen Involvement
por: Yoon, Michung
Publicado: (2010)

The PPARα and PPARγ Epigenetic Landscape in Cancer and Immune and Metabolic Disorders
por: Porcuna, Jesús, et al.
Publicado: (2021)

Role of PPARα in Hepatic Carbohydrate Metabolism
por: Peeters, Annelies, et al.
Publicado: (2010)

PPAR Agonists and Cardiovascular Disease in Diabetes
por: Calkin, Anna C., et al.
Publicado: (2008)

Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models
por: Chen, Ying, et al.
Publicado: (2013)

The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice
por: de la Rosa Rodriguez, Montserrat A., et al.
Publicado: (2018)

Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?
por: Scatena, Roberto, et al.
Publicado: (2008)

PPARγ agonists delay age‐associated metabolic disease and extend longevity
por: Xu, Lingyan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jkggatjefd121mj574qs9moe1r